The companies expand their collaboration for an additional two years to develop novel cancer immunotherapies. OBT will receive research funding & success-based development and regulatory milestones along with royalties on future product sales
Boehringer Ingelheim will lead the development and commercialization of treatment candidates that interact with the novel targets identified by OGAP under the terms of the extended agreement
The partnership b/w Oxford BioTherapeutics & Boehringer Ingelheim was initiated in Apr 2013 and Oct 2020 on the identification of novel tumor targets enabled by OBT’s OGAP discovery platform for Boehringer Ingelheim’s unique immuno-oncology and ADC platforms
Ref: Globenewswire | Image: Oxford BioTherapeutics
Related News:- Oxford BioTherapeutics Outlicenses Novel Antibody to Genmab for Immuno-Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
